Synergistic effects of high blood cholesterol and hypertension on leukocyte and platelet recruitment in the cerebral microcirculation

Hypertension

Volumn 63, Issue 4, 2014, Pages 747-752

  Rodrigues, Stephen F ^a   Almeida Paula, Lidiana D ^a   Granger, Daniel N ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

hypercholesterolemia; hypertension; inflammation

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; DEOXYCORTICOSTERONE ACETATE; LOSARTAN; LOSARTAN POTASSIUM; REACTIVE OXYGEN METABOLITE; RHODAMINE 6G; SUPEROXIDE; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL REACTIVITY; BODY WEIGHT; BRAIN MICROCIRCULATION; BRAIN WATER; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DEOXYCORTICOSTERONE-SALT INDUCED HYPERTENSION; FEEDING; FOOD INTAKE; HYPERCHOLESTEROLEMIA; LEUKOCYTE; LEUKOCYTE ADHERENCE; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ADHESION; VASCULARIZATION; VIDEO MICROSCOPY;

HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION;

ANIMALS; APOLIPOPROTEINS E; BLOOD PLATELETS; CELL ADHESION; CELL MOVEMENT; CEREBROVASCULAR CIRCULATION; CHOLESTEROL, DIETARY; COMORBIDITY; DESOXYCORTICOSTERONE ACETATE; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOCYTES; MALE; MICE; MICE, KNOCKOUT; PHENOTYPE; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84897037964     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02627     Document Type: Article

References (37)

1. Laslett LJ, Alagona P Jr, Clark BA III, Drozda JP Jr, Saldivar F, Wilson SR, Poe C, Hart M. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 suppl):S1-S49.
2. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
3. Lv J, Neal B, Ehteshami P, Ninomiya T, Woodward M, Rodgers A, Wang H, MacMahon S, Turnbull F, Hillis G, Chalmers J, Perkovic V. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001293.
4. Moura FA, Freitas WM, Sposito AC. Emergent cardiovascular risk factors in the very elderly. Expert Rev Cardiovasc Ther. 2012;10:1221-1225.
5. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110:1097-1108.
6. Rydén L, Mellbin L. Glucose perturbations and cardiovascular risk: challenges and opportunities. Diab Vasc Dis Res. 2012;9:170-176.
7. Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag. 2012;8:323-331.
8. Ishikawa M, Stokes KY, Zhang JH, Nanda A, Granger DN. Cerebral microvascular responses to hypercholesterolemia: roles of NADPH oxi-dase and P-selectin. Circ Res. 2004;94:239-244.
9. Rodrigues SF, Granger DN. Cerebral microvascular infammation in DOCA salt-induced hypertension: role of angiotensin II and mitochon-drial superoxide. J Cereb Blood Flow Metab. 2012;32:368-375.
10. Vital SA, Terao S, Nagai M, Granger DN. Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension. Microcirculation. 2010;17:641-649.
11. Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T. Angiotensin II induced cerebral microvascular infammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience. 2010;171:852-858.
12. Jiang X, Guo M, Su J, Lu B, Ma D, Zhang R, Yang L, Wang Q, Ma Y, Fan Y. Simvastatin blocks blood-brain barrier disruptions induced by elevated cholesterol both in vivo and in vitro. Int J Alzheimers Dis. 2012;2012:109324.
13. Gordon DB, Nogueira A. Increased vascular reactivity in experimental hypertension. Circ Res. 1962;10:269-273.
14. Heric E, Tackett RL. Altered vascular reactivity in the rabbit during hyper-cholesterolemia. Pharmacology. 1985;31:72-81.
15. Kurtel H, Rodrigues SF, Yilmaz CE, Yildirim A, Granger DN. Impaired vasomotor function induced by the combination of hypertension and hypercholesterolemia. J Am Soc Hypertens. 2013;7:14-23.
16. Rodrigues SF, Vital SA, Granger DN. Mild hypercholesterolemia blunts the proinfammatory and prothrombotic effects of hypertension on the cerebral microcirculation. J Cereb Blood Flow Metab. 2013;33:483-489.
17. Ishikawa M, Vowinkel T, Stokes KY, Arumugam TV, Yilmaz G, Nanda A, Granger DN. CD40/CD40 ligand signaling in mouse cerebral microvascu-lature after focal ischemia/reperfusion. Circulation. 2005;111:1690-1696.
18. Uyama O, Okamura N, Yanase M, Narita M, Kawabata K, Sugita M. Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans blue fuorescence. J Cereb Blood Flow Metab. 1988;8:282-284.
19. Hayek T, Ito Y, Azrolan N, Verdery RB, Aalto-Setälä K, Walsh A, Breslow JL. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest. 1993;91:1665-1671.
20. Tian J, Pei H, James JC, Li Y, Matsumoto AH, Helm GA, Shi W. Circulating adhesion molecules in apoE-defcient mouse strains with different atherosclerosis susceptibility. Biochem Biophys Res Commun. 2005;329:1102-1107.
21. Arruda RM, Peotta VA, Meyrelles SS, Vasquez EC. Evaluation of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. Hypertension. 2005;46:932-936.
22. Jin SX, Shen LH, Nie P, Yuan W, Hu LH, Li DD, Chen XJ, Zhang XK, He B. Endogenous renovascular hypertension combined with low shear stress induces plaque rupture in apolipoprotein E-defcient mice. Arterioscler Thromb Vasc Biol. 2012;32:2372-2379.
23. Cassis LA, Gupte M, Thayer S, Zhang X, Charnigo R, Howatt DA, Rateri DL, Daugherty A. ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol. 2009;296:H1660-H1665.
24. Pellegrin M, Alonso F, Aubert JF, Bouzourene K, Braunersreuther V, Mach F, Haefiger JA, Hayoz D, Berthelot A, Nussberger J, Laurant P, Mazzolai L. Swimming prevents vulnerable atherosclerotic plaque development in hypertensive 2-kidney, 1-clip mice by modulating angiotensin II type 1 receptor expression independently from hemodynamic changes. Hypertension. 2009;53:782-789.
25. Weiss D, Taylor WR. Deoxycorticosterone acetate salt hypertension in apolipoprotein E-/-mice results in accelerated atherosclerosis: the role of angiotensin II. Hypertension. 2008;51:218-224.
26. Rosenbaugh EG, Savalia KK, Manickam DS, Zimmerman MC. Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol. 2013;304:R917-R928.
27. Methia N, André P, Hafezi-Moghadam A, Economopoulos M, Thomas KL, Wagner DD. ApoE defciency compromises the blood brain barrier especially after injury. Mol Med. 2001;7:810-815.
28. Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Dhaliwal SS, Mamo JC. Probucol prevents blood-brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding. Clin Exp Pharmacol Physiol. 2013;40:45-52.
29. Pelisch N, Hosomi N, Mori H, Masaki T, Nishiyama A. RAS inhibition attenuates cognitive impairment by reducing blood-brain barrier permeability in hypertensive subjects. Curr Hypertens Rev. 2013;9:93-98.
30. 2 nanoparticles exposure at high ambient temperature. Mol Neurobiol. 2013;48:368-379.
31. Werber AH, Fitch-Burke MC. Effect of chronic hypertension on acute hypertensive disruption of the blood-brain barrier in rats. Hypertension. 1988;12:549-555.
32. Patel BM, Mehta AA. Aldosterone and angiotensin: role in diabetes and cardiovascular diseases. Eur J Pharmacol. 2012;697:1-12.
33. Haack D, Möhring J, Möhring B, Petri M, Hackenthal E. Comparative study on development of corticosterone and DOCA hypertension in rats. Am J Physiol. 1977;233:F403-F411.
34. Erdos B, Kirichenko N, Whidden M, Basgut B, Woods M, Cudykier I, Tawil R, Scarpace PJ, Tumer N. Effect of age on high-fat diet-induced hypertension. Am J Physiol Heart Circ Physiol. 2011;301:H164-H172.
35. Schäfer T, Sperling J, Kollmar O, Richter S, Schilling MK, Menger MD, Lindemann W. Early effect of hepatic artery TNF-alpha infusion on systemic hemodynamics and infammation: a dose-response study in pigs. Int J Colorectal Dis. 2010;25:523-532.
36. Wilcox PG, Wakai Y, Walley KR, Cooper DJ, Road J. Tumor necrosis factor alpha decreases in vivo diaphragm contractility in dogs. Am J Respir Crit Care Med. 1994;150(5 Pt 1):1368-1373.
37. Kataoka H, Murakami R, Numaguchi Y, Okumura K, Murohara T. Angiotensin II type 1 receptor blockers prevent tumor necrosis factor-alpha-mediated endothelial nitric oxide synthase reduction and superoxide production in human umbilical vein endothelial cells. Eur J Pharmacol. 2010;636:36-41.